The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...

Hepatocellular carcinoma is a cancer that starts in your liver. It's different from "secondary" liver cancers, which have spread to the liver from other organs. If caught early, it can sometimes ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission ...

Researchers identify a history of GI bleeding and three other factors as elevating variceal bleeding risk in patients ...

European Commission approves Bristol Myers Squibb’s Opdivo plus Yervoy for first-line treatment of adult patients with unresectable or advanced HCC: Princeton, New Jersey Monday ...

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new ...

Fluorescence navigation is a novel technique for accurately identifying hepatocellular carcinoma (HCC) lesions during hepatectomy, enabling real-time visualization. Indocyanine green-based ...

Plectin drives hepatocellular carcinoma progression and metastasis through cytoskeletal reorganization and oncogenic signaling, making it a promising therapeutic target for overcoming therapy ...

Discover why, to improve screening efficiency, it is crucial to identify patients with elevated hepatocellular carcinoma risk ...

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer in Switzerland and worldwide. Immunotherapy through ...

Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...